J&J CFO Wolk on Orthopedics Spinoff, Earnings, Drug Pricing

Core Insights - Johnson & Johnson is positioned for a strong performance in 2026, with plans to spin off its slower-growing orthopedics business [1] - The company reported third-quarter sales and earnings that modestly exceeded expectations, leading to an increase in revenue guidance for the full year [1] Financial Performance - Third-quarter sales and earnings surpassed market expectations, indicating robust operational performance [1] - The company has raised its revenue guidance for the full year, reflecting confidence in its financial outlook [1] Strategic Plans - Johnson & Johnson plans to spin off its orthopedics business, which is characterized by slower growth, to focus on more lucrative segments [1]